* ESSA Pharma Inc EPIX.OQ EPIX.O is expected to show no
change
in quarterly revenue when it reports results on May 8
(estimated).
*
* Refinitiv's mean analyst estimate for ESSA Pharma Inc is
for a
loss of 20 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for ESSA Pharma
Inc
is $21, above its last closing price of $2.94.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.22 -0.23 -0.15 Beat 36.2
Sep. 30 2022 -0.27 -0.14 Beat 49.1
Jun. 30 2022 -0.28 -0.27 -0.20 Beat 25.9
Mar. 31 2022 -0.26 -0.25 -0.25 Met 1
Dec. -0.23 -0.23 -0.21 Beat 8.7
31 2021
Sep. 30 2021 -0.22 -0.23 -0.20 Beat 14
Jun. 30 2021 -0.26 -0.26 -0.21 Beat 20
Mar. 31 2021 -0.21 -0.21 -0.36 Missed -68.2
This summary was machine generated May 5 at 15:30 GMT. All
figures in US dollars unless otherwise stated